139 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
.
First Quarter Financial Results
Research and development (R&D) expenses for the first quarter of 2024 were $3.0 million, compared with $3.9 million … , except per share data)
Three months ended March 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
8-K
EX-99.1
jjofa exw
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
qkoo7rxkv vtjuwt5
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
EX-99.1
21nqomrfw fy
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
j89jna
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
r8iwyrsr ccanl7l5t1
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
oaehjd90avf35
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
7rtwg0 k1osglw2
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am